Lymphoepithelioma-like carcinoma of the urinary bladder - Revision history

Michael at 14:50, 4 August 2022

2022-08-04T14:50:28Z

← Older revision		Revision as of 14:50, 4 August 2022
Line 9:		Line 9:
	\| LMDDx = [[lymphoma]], [[urothelial carcinoma]] and inflammation, metastatic [[lymphoepithelioma-like carcinoma]]		\| LMDDx = [[lymphoma]], [[urothelial carcinoma]] and inflammation, metastatic [[lymphoepithelioma-like carcinoma]]
	\| Stains =		\| Stains =
	\| IHC = CK34betaE12 +ve, p63 +ve/-ve, CK7 +ve/-ve, CK20 -ve, CD30 -ve		\| IHC = [[CK34betaE12]] +ve, p63 +ve/-ve, [[CK7]] +ve/-ve, [[CK20]] -ve, CD30 -ve
	\| EM =		\| EM =
	\| Molecular =		\| Molecular =

Michael: fix

2019-07-31T18:58:34Z

fix

← Older revision		Revision as of 18:58, 31 July 2019
Line 62:		Line 62:
	</gallery>		</gallery>
	www:		www:
	*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881438/figure/F0002/ LELC of the urinary bladder - low mag. (nih.gov)].<ref name=pmid19847088>{{Cite journal \| last1 = Singh \| first1 = NG. \| last2 = Mannan \| first2 = AA. \| last3 = Rifaat \| first3 = AA. \| last4 = Kahvic \| first4 = M. \| title = Lymphoepithelioma-like carcinoma of the urinary bladder: report of a rare case. \| journal = Ann Saudi Med \| volume = 29 \| issue = 6 \| pages = 478-81 \| month = \| year = \| doi = 10.4103/0256-4947.57173 \| PMID = 19847088 }}		*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881438/figure/F0002/ LELC of the urinary bladder - low mag. (nih.gov)].<ref name=pmid19847088>{{Cite journal \| last1 = Singh \| first1 = NG. \| last2 = Mannan \| first2 = AA. \| last3 = Rifaat \| first3 = AA. \| last4 = Kahvic \| first4 = M. \| title = Lymphoepithelioma-like carcinoma of the urinary bladder: report of a rare case. \| journal = Ann Saudi Med \| volume = 29 \| issue = 6 \| pages = 478-81 \| month = \| year = \| doi = 10.4103/0256-4947.57173 \| PMID = 19847088 }}</ref>
	</ref>
	*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881438/figure/F0003/ LELC of the urinary bladder - high mag. (nih.gov)].<ref name=pmid19847088/>		*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881438/figure/F0003/ LELC of the urinary bladder - high mag. (nih.gov)].<ref name=pmid19847088/>

Michael: /* Microscopic */

2018-10-25T14:44:05Z

Microscopic

← Older revision		Revision as of 14:44, 25 October 2018
Line 44:		Line 44:
	*Prominent lymphoid infiltrate - '''key feature'''.		*Prominent lymphoid infiltrate - '''key feature'''.
	*+/-[[Urothelial carcinoma in situ]].		*+/-[[Urothelial carcinoma in situ]].

			Note:
			*Peritumoural lymphoid aggregates are typical.<ref name=pmid19847088>{{Cite journal \| last1 = Singh \| first1 = NG. \| last2 = Mannan \| first2 = AA. \| last3 = Rifaat \| first3 = AA. \| last4 = Kahvic \| first4 = M. \| title = Lymphoepithelioma-like carcinoma of the urinary bladder: report of a rare case. \| journal = Ann Saudi Med \| volume = 29 \| issue = 6 \| pages = 478-81 \| month = \| year = \| doi = 10.4103/0256-4947.57173 \| PMID = 19847088 }}</ref>

	DDx:		DDx:

Michael at 16:42, 13 October 2015

2015-10-13T16:42:08Z

← Older revision		Revision as of 16:42, 13 October 2015
Line 6:		Line 6:
	\| Synonyms =		\| Synonyms =
	\| Micro = squamoid cells with abundant dense cytoplasm central nuclei +/- small/indistinct nucleoli, prominent lymphoid infiltrate		\| Micro = squamoid cells with abundant dense cytoplasm central nuclei +/- small/indistinct nucleoli, prominent lymphoid infiltrate
	\| Subtypes = subtype of [[urothelial carcinoma]]		\| Subtypes = (subtype of [[urothelial carcinoma]])
	\| LMDDx = [[lymphoma]], [[urothelial carcinoma]] and inflammation, metastatic [[lymphoepithelioma-like carcinoma]]		\| LMDDx = [[lymphoma]], [[urothelial carcinoma]] and inflammation, metastatic [[lymphoepithelioma-like carcinoma]]
	\| Stains =		\| Stains =

Michael at 09:06, 6 September 2015

2015-09-06T09:06:13Z

← Older revision		Revision as of 09:06, 6 September 2015
Line 25:		Line 25:
	\| Rads =		\| Rads =
	\| Endoscopy =		\| Endoscopy =
	\| Prognosis =		\| Prognosis = favourable on limited data
	\| Other = not associated with [[EBV]]		\| Other = not associated with [[EBV]]
	\| ClinDDx =		\| ClinDDx =

Michael: /* General */

2015-09-06T09:05:37Z

General

← Older revision		Revision as of 09:05, 6 September 2015
Line 35:		Line 35:
	*Rare.		*Rare.
	*Not associated with [[EBV]].<ref name=pmid21383609>{{Cite journal \| last1 = Williamson \| first1 = SR. \| last2 = Zhang \| first2 = S. \| last3 = Lopez-Beltran \| first3 = A. \| last4 = Shah \| first4 = RB. \| last5 = Montironi \| first5 = R. \| last6 = Tan \| first6 = PH. \| last7 = Wang \| first7 = M. \| last8 = Baldridge \| first8 = LA. \| last9 = MacLennan \| first9 = GT. \| title = Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. \| journal = Am J Surg Pathol \| volume = 35 \| issue = 4 \| pages = 474-83 \| month = Apr \| year = 2011 \| doi = 10.1097/PAS.0b013e31820f709e \| PMID = 21383609 }}</ref>		*Not associated with [[EBV]].<ref name=pmid21383609>{{Cite journal \| last1 = Williamson \| first1 = SR. \| last2 = Zhang \| first2 = S. \| last3 = Lopez-Beltran \| first3 = A. \| last4 = Shah \| first4 = RB. \| last5 = Montironi \| first5 = R. \| last6 = Tan \| first6 = PH. \| last7 = Wang \| first7 = M. \| last8 = Baldridge \| first8 = LA. \| last9 = MacLennan \| first9 = GT. \| title = Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. \| journal = Am J Surg Pathol \| volume = 35 \| issue = 4 \| pages = 474-83 \| month = Apr \| year = 2011 \| doi = 10.1097/PAS.0b013e31820f709e \| PMID = 21383609 }}</ref>
			*Good prognosis on scant data<ref>{{Cite journal \| last1 = Fujino \| first1 = T. \| last2 = Kubota \| first2 = M. \| last3 = Nishiyama \| first3 = R. \| last4 = Kanno \| first4 = T. \| last5 = Okada \| first5 = T. \| last6 = Higashi \| first6 = Y. \| last7 = Yamada \| first7 = H. \| last8 = Okamoto \| first8 = E. \| title = [A case of lymphoepithelioma-like carcinoma of the bladder]. \| journal = Hinyokika Kiyo \| volume = 60 \| issue = 10 \| pages = 507-11 \| month = Oct \| year = 2014 \| doi = \| PMID = 25391783 }}</ref> - possibly poor if metastatic.

	==Microscopic==		==Microscopic==

Michael: /* See also */

2015-09-05T20:26:21Z

Michael: /* Microscopic */

2015-09-05T20:22:52Z

Microscopic

← Older revision		Revision as of 20:22, 5 September 2015
Line 41:		Line 41:
	**Abundant dense cytoplasm.		**Abundant dense cytoplasm.
	**Central nuclei +/- small/indistinct nucleoli.		**Central nuclei +/- small/indistinct nucleoli.
	**Surrounded by a prominent lymphoid ~~component~~ - '''key feature'''.		*Prominent lymphoid infiltrate - '''key feature'''.
	*+/-[[Urothelial carcinoma in situ]].		*+/-[[Urothelial carcinoma in situ]].

Michael at 20:21, 5 September 2015

2015-09-05T20:21:59Z

← Older revision		Revision as of 20:21, 5 September 2015
Line 9:		Line 9:
	\| LMDDx = [[lymphoma]], [[urothelial carcinoma]] and inflammation, metastatic [[lymphoepithelioma-like carcinoma]]		\| LMDDx = [[lymphoma]], [[urothelial carcinoma]] and inflammation, metastatic [[lymphoepithelioma-like carcinoma]]
	\| Stains =		\| Stains =
	\| IHC =		\| IHC = CK34betaE12 +ve, p63 +ve/-ve, CK7 +ve/-ve, CK20 -ve, CD30 -ve
	\| EM =		\| EM =
	\| Molecular =		\| Molecular =
Line 64:		Line 64:
	==IHC==		==IHC==
	Features:<ref name=pmid21383609/>		Features:<ref name=pmid21383609/>
	*p53 +ve/-ve.		*p53 +ve/-ve. (+ve in ~60% of cases).
			*CK34betaE12 +ve (+ve in ~75% of cases).
			*CK7 +ve/-ve (+ve in ~60% of cases).
			*p63 +ve/-ve (+ve in ~50% of cases).

			Others:<ref name=pmid21383609/>
	*CK20 -ve.		*CK20 -ve.
	*TTF-1 -ve.		*TTF-1 -ve.
	*CD30 -ve.		*CD30 -ve.
	*CK34betaE12 +ve (+ve in 75% of cases).
	*CK7 +ve/-ve (+ve in ~60% of cases).
	*p63 +ve/-ve (+ve in ~50% of cases).

	==See also==		==See also==

Michael at 20:19, 5 September 2015

2015-09-05T20:19:38Z

← Older revision		Revision as of 20:19, 5 September 2015
Line 42:		Line 42:
	**Central nuclei +/- small/indistinct nucleoli.		**Central nuclei +/- small/indistinct nucleoli.
	**Surrounded by a prominent lymphoid component - '''key feature'''.		**Surrounded by a prominent lymphoid component - '''key feature'''.
			*+/-[[Urothelial carcinoma in situ]].

	DDx:		DDx:
Line 60:		Line 61:
	</ref>		</ref>
	*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881438/figure/F0003/ LELC of the urinary bladder - high mag. (nih.gov)].<ref name=pmid19847088/>		*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881438/figure/F0003/ LELC of the urinary bladder - high mag. (nih.gov)].<ref name=pmid19847088/>

			==IHC==
			Features:<ref name=pmid21383609/>
			*p53 +ve/-ve.
			*CK20 -ve.
			*TTF-1 -ve.
			*CD30 -ve.
			*CK34betaE12 +ve (+ve in 75% of cases).
			*CK7 +ve/-ve (+ve in ~60% of cases).
			*p63 +ve/-ve (+ve in ~50% of cases).

	==See also==		==See also==

← Older revision		Revision as of 20:26, 5 September 2015
Line 77:		Line 77:
	*[[Urothelial carcinoma]].		*[[Urothelial carcinoma]].
	*[[Urinary bladder]].		*[[Urinary bladder]].
			*[[Lymphoepithelioma-like carcinoma]].
			*[[Nasopharyngeal carcinoma]].

	==References==		==References==